Recent studies have demonstrated that ANGPTL3 suppression by antibody or antisense oligonucleotides represents a new therapeutic strategy to reduce plasma LDL cholesterol and TG levels for patients with dyslipidemia [12, 14, 15]. This evidence concerns the gene ANGPTL3 and metabolic syndrome.